We have updated our Privacy Policy to comply with the new requirements under the EU General Data Protection Regulation (GDPR), effective May 25, 2018.
By clicking "Complete Login", you agree with Practice Point Communication's Privacy Policy and Terms of Use.
These certified AMA/ANCC/ACPE activities feature a discussion among three experts that will review the current and emerging treatment landscape of high-risk myelodysplastic syndromes (MDS). The program includes two activities that will feature the faculty discussing recent updates in the standard of care for high-risk MDS and what is on the horizon for high-risk MDS.
Supported by independent educational grants from Genentech, Novartis, Taiho and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited